InspireMD Inc (NSPR) - Net Assets

Latest as of March 2026: $43.62 Million USD

Based on the latest financial reports, InspireMD Inc (NSPR) has net assets worth $43.62 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($56.47 Million) and total liabilities ($12.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NSPR intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets $43.62 Million
% of Total Assets 77.24%
Annual Growth Rate 84.4%
5-Year Change 64.62%
10-Year Change 1264.67%
Growth Volatility 118.45

InspireMD Inc - Net Assets Trend (2008–2025)

This chart illustrates how InspireMD Inc's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of InspireMD Inc to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for InspireMD Inc (2008–2025)

The table below shows the annual net assets of InspireMD Inc from 2008 to 2025. For live valuation and market cap data, see InspireMD Inc market capitalisation.

Year Net Assets Change
2025-12-31 $55.20 Million +52.97%
2024-12-31 $36.09 Million -8.65%
2023-12-31 $39.50 Million +127.11%
2022-12-31 $17.39 Million -48.13%
2021-12-31 $33.53 Million +175.69%
2020-12-31 $12.16 Million +125.95%
2019-12-31 $5.38 Million -38.57%
2018-12-31 $8.76 Million +221.34%
2017-12-31 $2.73 Million -32.58%
2016-12-31 $4.04 Million +237.30%
2015-12-31 $-2.95 Million -5.71%
2014-12-31 $-2.79 Million -151.44%
2013-12-31 $5.42 Million +0.59%
2012-12-31 $5.39 Million +0.07%
2012-06-30 $5.38 Million -0.07%
2011-12-31 $5.39 Million +234172.14%
2010-12-31 $-2.30K 0.00%
2009-12-31 $-2.30K -237.37%
2008-12-31 $1.68K --

Equity Component Analysis

This analysis shows how different components contribute to InspireMD Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 30228117500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $4.00K 0.01%
Other Components $357.49 Million 647.61%
Total Equity $55.20 Million 100.00%

InspireMD Inc Competitors by Market Cap

The table below lists competitors of InspireMD Inc ranked by their market capitalization.

Company Market Cap
Kunming Longjin Pharmaceutical Co Ltd
SHE:002750
$34.58 Million
NXT Energy Solutions Inc
TO:SFD
$34.58 Million
Shandong Chenming Paper Holdings Limited
F:SCD1
$34.59 Million
Gunpoint Exploration Ltd
V:GUN
$34.59 Million
Novacyt
PA:ALNOV
$34.56 Million
INmune Bio Inc
NASDAQ:INMB
$34.56 Million
Hudson Global Inc
NASDAQ:HSON
$34.56 Million
Power Solution Technologies Public Company Limited
BK:PSTC
$34.56 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in InspireMD Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 36,086,000 to 55,201,000, a change of 19,115,000 (53.0%).
  • Net loss of 48,786,000 reduced equity.
  • New share issuances of 38,714,000 increased equity.
  • Other factors increased equity by 29,187,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-48.79 Million -88.38%
Share Issuances $38.71 Million +70.13%
Other Changes $29.19 Million +52.87%
Total Change $- 52.97%

Book Value vs Market Value Analysis

This analysis compares InspireMD Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.98x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has increased from 0.00x to 0.98x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2008-12-31 $307.34 $0.74 x
2009-12-31 $-328.71 $0.74 x
2010-12-31 $-328.71 $0.74 x
2011-12-31 $2821.37 $0.74 x
2012-12-31 $2821.37 $0.74 x
2013-12-31 $1727800.00 $0.74 x
2014-12-31 $-464500.00 $0.74 x
2015-12-31 $-267818.18 $0.74 x
2016-12-31 $72232.14 $0.74 x
2017-12-31 $1378.67 $0.74 x
2018-12-31 $284.80 $0.74 x
2019-12-31 $38.63 $0.74 x
2020-12-31 $8.04 $0.74 x
2021-12-31 $4.56 $0.74 x
2022-12-31 $2.21 $0.74 x
2023-12-31 $1.63 $0.74 x
2024-12-31 $0.86 $0.74 x
2025-12-31 $0.75 $0.74 x

Capital Efficiency Dashboard

This dashboard shows how efficiently InspireMD Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -88.38%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -543.33%
  • • Asset Turnover: 0.13x
  • • Equity Multiplier: 1.26x
  • Recent ROE (-88.38%) is above the historical average (-137.40%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2008 -228.36% -0.11% 692.59x 2.94x $-3.99K
2009 0.00% 0.00% 0.00x 0.00x $-23.75K
2010 0.00% -0.48% 832.77x 0.00x $-23.75K
2011 -326.72% -328.98% 0.33x 2.97x $-18.14 Million
2012 -326.72% -328.98% 0.33x 2.97x $-18.14 Million
2013 -338.67% -600.41% 0.23x 2.40x $-30.12 Million
2014 0.00% -890.53% 0.25x 0.00x $-24.82 Million
2015 0.00% -674.68% 0.40x 0.00x $-15.29 Million
2016 -209.17% -446.73% 0.20x 2.33x $-8.87 Million
2017 -309.42% -305.61% 0.45x 2.24x $-8.71 Million
2018 -82.62% -201.06% 0.29x 1.40x $-8.12 Million
2019 -186.51% -269.82% 0.38x 1.84x $-10.58 Million
2020 -86.69% -424.31% 0.14x 1.46x $-11.76 Million
2021 -44.49% -331.88% 0.11x 1.18x $-18.27 Million
2022 -106.31% -357.59% 0.21x 1.42x $-20.23 Million
2023 -50.42% -320.97% 0.13x 1.21x $-23.87 Million
2024 -88.69% -456.63% 0.15x 1.30x $-35.61 Million
2025 -88.38% -543.33% 0.13x 1.26x $-54.31 Million

Industry Comparison

This section compares InspireMD Inc's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $1,818,520,110
  • Average return on equity (ROE) among peers: -48.87%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
InspireMD Inc (NSPR) $43.62 Million -228.36% 0.29x $34.57 Million
Abbott Laboratories (ABT) $17.78 Billion 20.28% 1.23x $153.89 Billion
Adagio Medical Holdings, Inc Common Stock (ADGM) $19.91 Million -270.00% 1.43x $15.55 Million
Aethlon Medical Inc (AEMD) $-5.98 Million 0.00% 0.00x $2.51 Million
Acutus Medical Inc (AFIB) $126.58 Million -80.56% 0.52x $903.35K
Adapthealth Corp (AHCO) $280.85 Million -57.55% 5.46x $1.29 Billion
20/20 Biolabs, Inc. Common Stock (AIDX) $6.89 Million 30.07% 0.49x $6.67 Million
Allurion Technologies, Inc. (ALUR) $-70.49 Million 0.00% 0.00x $7.70 Million
Autonomix Medical, Inc. Common Stock (AMIX) $8.10 Million -140.88% 0.21x $4.44 Million
Artivion Inc (AORT) $17.90 Million 7.26% 0.20x $1.03 Billion
Apyx Medical Inc (APYX) $22.89 Million 2.69% 0.23x $176.29 Million

About InspireMD Inc

NASDAQ:NSPR USA Medical Devices
Market Cap
$34.57 Million
Market Cap Rank
#23328 Global
#5015 in USA
Share Price
$0.74
Change (1 day)
+3.59%
52-Week Range
$0.71 - $2.79
All Time High
$26625.00
About

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard c… Read more